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OBJECTIVES We designed a study to explore the effect of glycoprotein (GP) IIb/IIIa blockade on the
atherosclerotic plaque and distal coronary vasculature.
BACKGROUND Platelet GP IIb/IIIa blockers have been proven to be beneficial in acute ischemic syndromes.
This effect has also been attributed to the prevention of microvascular obstruction, although
the underlying mechanisms have not been fully defined.
METHODS Eighteen patients with unstable refractory angina pectoris underwent cardiac catheterization
and angioplasty. Trans-stenotic and microvascular resistances to flow were measured at
baseline, during hyperventilation, and after intracoronary adenosine. Measurements were
repeated early after abciximab administration and after successful percutaneous transluminal
coronary angioplasty.
RESULTS Hyperventilation induced an ischemic attack in 12 of 18 patients and increased epicardial
(12.8  16.9 vs. 6.1  6.1 mm Hg/ml per min, p  0.05) and microvascular (9.9  7.5 vs.
6.8  5.8 mm Hg/ml per min, p  0.05) coronary resistance. Abciximab had no significant
effect on epicardial resistance, although it significantly reduced distal coronary resistance
under all study conditions, including baseline (4.8  4.8 mm Hg/ml per min, p  0.01),
hyperventilation (5.1  5.4 mm Hg/ml per min, p  0.01), and intracoronary adenosine (2.7
 3.0 vs. 4.3 4.3 mm Hg/ml per min, p 0.05). The hyperventilation test became negative
in all patients after abciximab administration.
CONCLUSIONS These observations confirm the immediate beneficial effects of platelet GP IIb/IIIa blockade
with abciximab in acute ischemic syndromes and suggest that improvement of microvascular
function may play a central role in the mechanism of action of this drug. (J Am Coll Cardiol
2002;40:2102–9) © 2002 by the American College of Cardiology Foundation
Pathological and clinical studies have established that plate-
lets play a central role in the pathogenesis of acute coronary
syndromes. According to this concept, platelet inhibitors
have been proposed as the mainstay of therapy in patients
with acute coronary syndromes (1,2).
Three parenterally administered blocking agents of the
glycoprotein (GP) IIb/IIIa receptor have been tested in two
different clinical indications—namely, acute coronary syn-
dromes and percutaneous coronary interventions. In both
cases, these drugs showed a benefit (3). In unstable patients,
inhibition of GP IIb/IIIa reduced the mortality rate, rate of
myocardial infarction (MI), need for urgent revasculariza-
tion, and number and duration of ischemic episodes on
Holter monitoring (4,5). Moreover, among patients under-
going percutaneous transluminal coronary angioplasty
(PTCA), GP IIb/IIIa blockers reduced the rate of peri-
procedural complications (6–8).
Because the precipitation of acute ischemia is classically
attributed to thrombus formation on disrupted atheroscle-
rotic plaque, the beneficial effects of GP IIb/IIIa inhibition
have generally been attributed to passivation of active plaque
and reduction of thrombus burden (9). However, recent
studies have challenged the validity of this assumption. In
fact, GP IIb/IIIa blockers improved the outcome of high-
risk revascularization procedures, independent of either
their influence on intracoronary thrombus or baseline lesion
morphology (10,11). As an alternative mechanism of action,
a direct effect of abciximab on the microcirculation has been
reported following direct PTCA in acute MI (12). How-
ever, to the best of our knowledge, whether these agents
significantly affect microvascular control of perfusion in the
jeopardized myocardium has not been fully established.
The purpose of this study was to investigate the effects of
GP IIb/IIIa blockade on both atherosclerotic coronary
obstruction and the microcirculation in patients with acute
ischemic syndromes in order to gain insight into the
mechanism of action of these agents.
METHODS
Study population. Eighteen PTCA candidates (Table 1)
(12 men; age 61  13 years) were included in the study if
they met the following criteria: 1) clinical presentation
corresponding to Braunwald class IIIB acute unstable an-
gina; 2) electrocardiographic documentation of ischemia
resistant to maximal treatment, according to the Chimeric
7E3 AntiPlateleT in Unstable angina REfractory to stan-
dard treatment (CAPTURE) trial criteria (6); 3) no previ-
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ous MI; 4) single-vessel coronary artery disease suitable for
PTCA; and 5) preserved left ventricular function.
Study protocol. All patients were studied after they fasted
overnight, under active treatment with oral diltiazem and
aspirin, plus intravenous nitrates and heparin. In all pa-
tients, a bolus of isosorbide dinitrate (0.4 to 0.6 mg) was
injected through the guiding catheter, and a 0.014-in.
(0.035-cm) manometer tip guide wire (Radi Medical, Upp-
sala, Sweden) was positioned distal to the stenosis (13). A
2.5F catheter with a Doppler tip (Millar Instruments, Inc.,
Houston, Texas) was advanced over a 0.014-in. guide wire
in the culprit coronary artery and positioned proximally to
the obstruction. Care was taken not to have visible side
branches between the tip of the Doppler catheter and the
stenosis and to locate the catheter tip in the center of the
lumen, so as to obtain an optimal and stable velocity signal.
Stable blood flow and hemodynamics were verified for at
least 10 min before baseline recordings. Adenosine (2-mg
bolus) was selectively injected into the culprit artery through
the Doppler catheter. When flow velocity was back to
baseline, the hyperventilation test was performed.
Abciximab was administered as a 0.25-mg/kg bolus
followed by a continuous infusion of 10 g/min. The study
sequence (baseline/adenosine/hyperventilation) was re-
peated 15 to 20 min after the bolus.
The Doppler catheter was then removed, and an angio-
plasty catheter was advanced over the pressure wire. After
balloon dilation, a coronary stent of adequate size and
length was deployed in all patients.
Thereafter, the Doppler catheter was re-advanced in the
same position as in the pre-PTCA study, and measurements
of flow velocity and pressures were repeated before and after
intracoronary adenosine administration.
The following signals were continuously monitored and
recorded on paper when appropriate: 1) leads I, II, III, and
V4 of the surface electrocardiogram; 2) phasic and mean
aortic pressures; 3) phasic and mean distal coronary pres-
sures; and 4) phasic and mean coronary blood flow veloci-
ties.
Data analysis. Recordings (2.5 cm/s) were obtained at the
following times: 1) baseline; 2) 30 s after intracoronary
adenosine; 3) at maximal ST-segment shift and/or angina or
2 min after hyperventilation; 4) 15 to 20 min after abcix-
imab; 5) during the first balloon inflation; and 6) 15 min
after completion of the dilation procedure.
The vessel diameter at the catheter tip and the severity of
stenosis were measured off-line by quantitative angiography
(14). Angiography was performed before baseline and after
hyperventilation recordings, both before and during abcix-
imab infusion, although it was not performed after adeno-
sine administration. Coronary blood flow was calculated as:
mean blood flow velocity  vessel cross-sectional area.
Coronary epicardial resistance was calculated as the ratio of
the mean trans-stenotic pressure gradient to mean blood
flow. Coronary microvascular resistance was calculated as
the ratio of mean distal coronary pressure to mean blood
flow.
Coronary flow reserve (CFR) was defined as the ratio of
maximal flow to corresponding baseline flow. Fractional
flow reserve (FFR) was defined as the ratio of distal to aortic
Abbreviations and Acronyms
CFR  coronary flow reserve
FFR  fractional flow reserve
GP  glycoprotein
MI  myocardial infarction
PTCA  percutaneous transluminal coronary angioplasty
Table 1. Clinical and Angiographic Data of Study Patients
Patient
No.
Age
(yrs) Gender
ST-T–Segment
Changes at
Rest
Angina
at Rest
Duration of
Symptoms
LVEF
(%)
Diseased
Vessel
% Area Reduction
Before Abciximab
% Area Reduction
After Abciximab
% Area Reduction
After PTCA
1 79 M yes yes 4 years 56 LAD 92 94 19
2 74 F yes yes 1 year 52 LAD 93 96 16
3 58 F yes yes 1 year 57 LAD 99 99 18
4 64 M no no 2 weeks 61 LAD 96 97 16
5 51 M yes yes 3 months 53 LAD 95 93 19
6 42 M yes yes 2 months 61 LAD 96 92 12
7 64 M no yes 3 months 51 LAD 94 95 18
8 63 F no no 3 weeks 54 LAD 99 99 9
9 62 M yes yes 2 months 54 LAD 99 97 13
10 73 M yes yes 6 months 51 LAD 98 99 19
11 38 M yes yes 1 year 62 LAD 95 93 18
12 46 M yes yes 4 months 59 LCx 99 93 36
13 72 M yes yes 3 weeks 50 LAD 99 95 16
14 68 F yes yes 2 months 51 LAD 97 96 12
15 52 M yes yes 1 year 53 LAD 96 94 12
16 41 M yes yes 5 months 58 LAD 91 96 12
17 78 M no no 1 month 53 LCx 91 93 18
18 73 M yes yes 6 months 52 LAD 99 98 19
LAD  left anterior descending coronary artery; LCx  left circumflex coronary artery; LVEF  left ventricular ejection fraction; PTCA  percutaneous transluminal coronary
angioplasty.
2103JACC Vol. 40, No. 12, 2002 Marzilli et al.
December 18, 2002:2102–9 Abciximab and Microcirculation in Unstable Angina
pressure after adenosine administration. These two param-
eters were measured before treatment, after abciximab, and
after PTCA.
Statistical analysis. All data are expressed as the mean
value SD. Analysis of variance, followed by the Newman-
Keuls procedure for multiple comparisons and repeated
measures, was used to compare the heart rate, arterial and
distal coronary pressures, and values of both mean blood
flow and coronary resistance at the various stages of the
protocol. Linear regression analysis was performed by the
least-squares method. A p value 0.05 was considered
significant.
RESULTS
Clinical results. No patients complained of side effects as a
result of the study protocol. In no patient was atrioventric-
ular block requiring pacing observed.
Clinical and angiographic data are shown in Table 1. All
patients presented with a complex, tight lesion in the
ischemia-related vessel. The percent area stenosis was 96 
3%, which was not modified by abciximab (95  3%, p 
NS).
Hyperventilation induced ischemia in 12 of 18 patients.
Ischemic symptoms and signs completely disappeared by
151  37 s. As ischemia always occurred 2 min after the
stop of hyperventilation, flow values at this time were
considered in patients with a negative hyperventilation test.
After the abciximab bolus, the hyperventilation test became
consistently negative. Accordingly, in all patients, blood
flow and resistance values were calculated 2 min after the
stop of hyperventilation.
All patients underwent successful, uncomplicated dilation
and stenting of the culprit lesion. The residual area stenosis
was 17  6% (p  0.01 vs. baseline).
Coronary blood flow. Coronary hemodynamic data are
shown in Table 2. Intracoronary adenosine increased coro-
nary blood flow, with a CFR of 1.53  0.41. After
hyperventilation, coronary flow decreased. After abciximab,
higher flow values were observed under all study conditions
(Table 2). Abciximab also increased CFR to 1.71  0.54 (p
 0.05 vs. before treatment) (Fig. 1).
Angioplasty did not affect baseline blood flow, although it
increased the maximal flow capacity and CFR to 2.45 
1.42 (p  0.05 vs. abciximab before PTCA) (Fig. 1).
Coronary pressures. As shown in Table 2, a significant
trans-stenotic pressure gradient was present at baseline,
confirming the severity of the coronary obstruction. Mean
distal coronary pressure decreased after adenosine infusion,
giving an FFR of 0.49  0.12. Distal pressure did not
decrease during hyperventilation-induced ischemia. As a
consequence, despite the marked difference in flow values,
the driving pressures at the inlet of the coronary microcir-
culation, during both hyperventilation-induced ischemia
and adenosine-induced hyperemia, were similar.
Abciximab did not affect the post-stenotic coronary Ta
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pressure under any study condition. Thus, abciximab did
not affect either the trans-stenotic pressure gradient during
maximal vasodilation or FFR (from 0.49  0.12 to 0.49 
0.14, respectively; p  NS).
Balloon inflation caused an abrupt fall in distal coronary
pressure (average 20  10 mm Hg), which remained stable
throughout the occlusion time and was significantly (p 
0.01) lower than that at baseline, during adenosine vasodi-
lation, and during hyperventilation-induced ischemia.
Stenting virtually abolished the trans-stenotic pressure
gradient under all conditions. Accordingly, FFR markedly
increased to 0.94  0.05 (p  0.01 vs. pre-PTCA values
with or without abciximab) (Fig. 1). After stenting, no
patient had an FFR 0.85, although this parameter was
0.9 in 15 of 18 patients, indicating that most of the
epicardial resistance was actually caused by the severe
obstruction. Finally, FFR and CFR were not correlated
under any study conditions (Fig. 2).
Coronary resistance. As shown in Table 2 and Figure 3,
epicardial resistance to flow did not change with adenosine,
although it increased during hyperventilation. Abciximab
had no significant effect on epicardial resistance at baseline
or after adenosine infusion (Fig. 3), although it decreased
epicardial resistance after hyperventilation. In contrast,
PTCA virtually abolished the epicardial resistance to flow
under all study conditions.
Microvascular resistance decreased after adenosine infu-
sion and rose during hyperventilation. Abciximab induced a
significant reduction in microvascular resistance under all
study conditions (Table 2, Fig. 2). In contrast, PTCA did
Figure 1. The coronary flow reserve (CFR) (left) and fractional flow reserve (FFR) (right) responses to abciximab and percutaneous transluminal coronary
angioplasty (PTCA). Abciximab improved CFR but not FFR, indicating a greater effect of the drug on coronary microvascular function than on stenosis
severity. Data are shown as average values  SEM. *p  0.05 vs. baseline. °p  0.01 vs. baseline and abciximab.
Figure 2. Plots of coronary flow reserve (CFR) (y axis) and fractional flow reserve (FFR) (x axis) in all patients before treatment (left), during abciximab
infusion (center), and after stenting (right). No correlation was observed between these two descriptors of stenosis severity. After stenting, the persistence
of abnormal flow reserve was not caused by persistence of a pressure drop along the epicardial segment.
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not induce any significant change in microvascular resis-
tance at baseline or after adenosine.
DISCUSSION
The data of the present study document that GP IIb/IIIa
antagonism immediately improves myocardial blood flow
regulation in patients with acute coronary syndromes,
mostly because of the beneficial effect on the coronary
microcirculation. The reduction in coronary microvascular
resistance was similar under autoregulation and after max-
imal vasodilation with adenosine, ruling out a major effect of
abciximab on vasomotor tone regulation. Rather, in agree-
ment with recently published reports, these data suggest
that GP IIb/IIIa antagonism might prevent microvascular
obstruction, thus increasing the amount of myocardial mass
reached by perfusion.
Comparison with previous studies. Various studies have
shown that abciximab reduces the total ischemic burden in
patients with acute coronary syndromes and prevents ad-
verse cardiac events before and after percutaneous revascu-
larization in high-risk patients (6–8,11,15). These clinical
benefits have been mostly attributed to a reduction in
thrombus burden, leading to improved distal perfusion (9).
However, several investigators have challenged this hypoth-
esis: a possible or definite thrombus cannot be documented
in many unstable patients; the beneficial effects of abciximab
seem independent of baseline lesion morphology and the
presence of visible thrombus (10,11). Accordingly, alterna-
tive mechanisms, including improvement of microvascular
function and coronary blood flow regulation, have been
suggested (10–12).
Because angiographic measurements are poor indexes of
lesion burden and structure, we elected not to rely on subtle
angiographic changes to investigate the mechanism of
action of GP IIb/IIIa blockers. Rather, we performed
simultaneous measurements of intracoronary pressures and
flow velocities to assess the overall stenosis severity, inde-
pendent of lesion morphology and plaque composition.
This experimental setup permitted us to separate the drug
effect on the proximal stenotic segment from that on the
distal microvasculature.
The present study confirms the relevance of atheroscle-
rotic obstruction in the pathogenesis of unstable angina, as
all study patients had severe coronary stenosis, and its
removal by stenting virtually abolished the pressure gradi-
ent, followed by complete relief from angina. However, the
present data also confirm the role of an elevated microcir-
culatory vasoconstrictor tone in precipitating myocardial
ischemia in unstable patients. Indeed, in agreement with
previous observations (16), hyperventilation-induced isch-
emia was consistently associated with a paradoxical increase
in microvascular resistance.
The presence of a microvascular disorder in the post-
stenotic vascular bed is also confirmed by the lack of
normalization of coronary reserve after stenting, despite the
absence of a significant pressure drop along the epicardial
segment. Similarly, CFR and FFR were not correlated.
These findings partially disagree with the concept that
progressive stenosis decreases coronary reserve by dropping
the distal bed pressure relatively more for smaller increases
in flow (17). The lack of any correlation between these two
physiologic descriptors of stenosis severity might be ex-
plained by two considerations. On one hand, we only
selected patients with very severe stenosis, thus limiting the
variability of both parameters. On the other hand, a reduced
maximal flow capacity, caused by abnormal microvascular
dilation (18), limits the trans-stenotic pressure drop, thus
preserving FFR. Different degrees of microvascular dysfunc-
tion, associated with a narrow range of variation in stenosis
severity, might have prevented the recognition of a possible
relationship between CFR and FFR. Actually, the imme-
diate benefit seen with GP IIb/IIIa blockade was associated
Figure 3. Effect of abciximab on epicardial (left) and microvascular (right) coronary resistance. Data are shown as average values  SEM before treatment
(open circles connected by solid line), after abciximab (open squares connected by dashed line), and after stenting (solid triangles connected by dotted
line). Abciximab limited the increase of epicardial resistance induced by hyperventilation and significantly reduced microvascular resistance in the
jeopardized coronary vascular bed under all study conditions. *p  0.05 vs. corresponding baseline. °p  0.01 vs. corresponding condition without
abciximab. †p  0.01 vs. corresponding condition after abciximab.
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with an improvement in coronary microvascular function.
More specifically, abciximab lowered microvascular resis-
tances to flow under all study conditions, including baseline,
adenosine-induced vasodilation, and hyperventilation-
induced vasoconstriction. At unchanged epicardial stenosis,
this distal effect would imply a greater trans-stenotic pres-
sure gradient and lower FFR. This phenomenon was not
observed, indicating some degree of vasodilation also at the
epicardial segment. However, the absence of significant
effects of abciximab on stenosis resistance, both under
autoregulation and at maximal vasodilation, makes it un-
likely that this is the major site of action of the drug. Finally,
it is interesting that this piece of information could only be
obtained by the simultaneous measurement of resistance in
both the epicardial artery and distal coronary microcircula-
tion. Increases in flow or coronary reserve values could not
identify, per se, the site of action of the drug. In contrast,
the isolated measurements of coronary pressures and FFR
would not have identified any improvement in coronary
hemodynamics.
Mechanism of action of abciximab. These observations
offer an alternative explanation for the clinical benefits of
anti-platelet agents. First of all, these data suggest that,
besides changes in plaque structure and morphology, mi-
crovascular phenomena might contribute to precipitating
ischemia in unstable patients. Although the mechanism(s)
of the paradoxical constriction of the coronary microcircu-
lation during ischemia are largely unknown, some reports
suggest that platelets might interfere with microvascular
regulation of coronary blood flow (19,20). Platelets may be
activated by exposure to thrombus, injured endothelium,
and collagen while crossing the stenotic segment (1). Acti-
vated platelets can affect microvascular resistance by micro-
embolization and/or release of constrictive, pro-adhesive,
and pro-inflammatory factors. Along this line, acute isch-
emic syndromes are often associated with evidence of
microvascular obstruction (21). Although this phenomenon
is generally attributed to microembolization from the epi-
cardial thrombus, it has been documented that interaction
with adhesion molecules prevents microvascular obstruction
in experimental models of ischemia without coronary
thrombosis (22).
In the present study, abciximab improved baseline and
maximal blood flow, as well as vasodilator reserve. In
particular, abciximab decreased minimal microvascular re-
sistance (i.e., this drug decreased the resistance of an already
maximally dilated microvasculature). It seems conceivable
that this additive effect on the large dose of adenosine might
not reflect an exclusive improvement of microvascular tone
regulation. Rather, this finding strongly suggests the pre-
vention of microvascular obstruction, leading to an increase
in the vascular bed reached by perfusion both at baseline and
during maximal vasodilation. These observations support
the concept that GP IIb/IIIa blockade prevents the negative
interaction between activated platelets and microvascular
function. This concept has already been suggested by others
in the setting of primary PTCA and acute MI (12,23), as
well as by studies documenting the beneficial effects of
abciximab, as an adjunct to fibrinolytic therapy, on clinical
and angiographic correlates of myocardial reperfusion (24).
Therefore, it seems possible that the microvascular action of
abciximab might have been caused by a peculiar receptor
affinity leading to effects not strictly related to the GP
IIb/IIIa antagonism (23).
Study limitations. This was an open study of a small group
of highly selected patients, and it exclusively explored the
short-term effects of GP IIb/IIIa blockade. Additional
mechanisms may come into play with prolonged infusion of
abciximab or with administration of GP IIb/IIIa antagonists
with a longer half-life.
We did not perform platelet function tests in our patients.
Therefore, we are attributing the effects we observed to
platelet inhibition, but we cannot exclude additional mech-
anisms, including direct, non-platelet-mediated actions of
abciximab on the coronary microcirculation. As a matter of
fact, abciximab has equipotent affinity for the vitronectin
receptor and demonstrates affinity for the CD11b/18
(Mac-1) receptors, as well (23). Moreover, abciximab has
been demonstrated to inhibit leukocyte adhesion and trans-
migration across the endothelium (25) and the formation of
both monocyte-platelet and neutrophil-platelet aggregates
(26). All of these actions could influence the coronary
microcirculation and appear to be modulated by non–GP
IIb/IIIa receptor mediated mechanisms. In fact, pure GP
IIb/IIIa receptor blockade did not appear to reduce the
white cell content in the infarcted myocardium, as reflected
by myeloperoxidase activity after coronary occlusion in an
animal model (27). Accordingly, a comparison of the
observations made with abciximab to similar measurements
made after administration of a more pure GP IIb/IIIa
receptor antagonist, such as eptifibatide, tirofiban, or
10E5Mab, might provide more direct insight into the
relative role of platelet GP IIb/IIIa blockade and possible
extension of these data to a class effect of GP IIb/IIIa
inhibitors.
The hyperventilation test has largely been used as a
clinical tool to induce coronary spasm. The sensitivity and
specificity of this test for the diagnosis of coronary spasm
have been reported to be as high as 62% and 100%,
respectively (28). However, coronary constriction at the site
of atherosclerotic stenoses has been shown to play an
important role in modulating the frequency and severity of
symptoms in patients with exertional angina and atheroscle-
rotic coronary artery disease (29,30). By triggering coronary
constriction, hyperventilation can precipitate angina in un-
stable patients with severe stenosis. In the present study, the
hyperventilation test was positive in 67% of patients; it
became negative after abciximab. However, it should also be
noted that nitrates were administered in all patients at the
beginning of the study, and this might have interfered with
the ischemic response. Moreover, the present data do not
provide any insight into either the mechanism by which
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hyperventilation triggers general vasoconstriction or the
pathways underlying the effect of treatment on the response
to this test.
We are fully aware that the dose of adenosine that we
used in this as well as previous studies largely exceeds the
recommended dosages. However, with dose-response curve
studies, we found that a bolus injection 1 mg is needed to
ensure maximal microvascular dilation to accurately measure
both FFR and CFR (31). Experience in large patient
populations has shown that this approach is well tolerated
and free of adverse side effects under different clinical
conditions, including normal subjects (32), hypertensive
patients (33), patients with stable (32,34) or unstable (16)
angina, and patients with acute MI (35). Our clinical
protocol is also corroborated by the findings of Shryock et
al. (36), who documented large type A2 receptors for
adenosine reserve, implying that although very small doses
of drug can induce a large submaximal vasodilation, very
large doses are needed to guarantee the maximal effect.
Conclusions. Platelet inhibition by GP IIb/IIIa blockade
with abciximab markedly improved microvascular function.
This effect was independent of changes in stenosis severity,
was evident before arterial lumen enlargement by balloon
angioplasty, and was associated with an improvement in the
ischemic threshold. These observations confirm the imme-
diate clinical benefits of abciximab and offer a possible
explanation for the reduction of ischemic events observed
early after drug infusion in refractory unstable angina (6).
Further studies are needed to verify whether this effect is
specific to this drug or is shared by other molecules.
However, these observations emphasize the need for devel-
oping new, orally active, long-lasting anti-platelet agents
capable of passivating acute ischemic patients and prevent-
ing patient destabilization.
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